Research Article of Journal of Pharmaceutical Research and Reviews
Chemometrically Assisted RP-HPLC and Spectroscopic Method Development for Simultaneous Multi-Component Analysis of Ledipasvir and Sofosbuvir in Pure and Pharmaceutical Formulation
Roma N. Trivedi*1, Jinal N. Tandel1, Samir K. Shah2
1Department of Quality Assurance, Sardar Patel College of Pharmacy, Vidyanagar-Vadtal Road, Bakrol, (388315) Gujarat, India
2Department of Pharmacology, Sardar Patel College of Pharmacy, Vidyanagar-Vadtal Road, Bakrol, (388315) Gujarat, India
Hepatitis C virus (HCV) is an RNA virus that chronically infects about 71 million individuals worldwide . Approximately 80% of acutely infected HCV patients progress to chronic infection, 20% of whom develop cirrhosis within 25 years, with 25 % of patients with cirrhosis developing hepatocellular carcinoma and/or decompensated liver disease. There are six major HCV genotypes with many subtypes based on genomic sequence heterogeneity. Since the discovery of HCV in 1989, strategies to cure the infection have evolved dramatically. A cure is defined as a sustained virologic response and consists of undetectable levels of plasma HCV RNA 12 or 24 weeks after completion of therapy. Among the people who have chronic HCV infection, approximately 60% have the genotype 1 strain of the virus. The treatment of patients infected with HCV genotype 1 is rapidly evolving. HCV therapy has been recently revolutionized by the development and approval of direct-acting antiviral agents (DAAs), borne out of the intense study of the viral life cycle and the elucidation of the crystal structure of several critical viral proteins [2,3].
Ledipasvir and Sofosbuvir in combination are directly acting antivirals attacking at the former stage of replication, reducing the disease leading to its chronicity. SOF is chemically known as (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3hydroxy-4-methyl tetrahydrofuran-2-yl)methoxy)-(phenoxy) phosphorylamino) propanoate (Fig.1a). It has a molecular formula of C22H29FN3O9P and a molecular weight of 529.54. Sofosbuvir is white to off-white powder with a solubility of ≥ 2 mg/mL across the pH range of 2-7.7 at 37°C. The partition coefficient (log P) for Sofosbuvir is 1.62 and the pKa is 9.3. Sofosbuvir is a pangenotypic inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication [4,5].
Keywords: RP-HPLC and Spectroscopic Method Development, Simultaneous Multi-Component Analysis, Ledipasvir and Sofosbuvir, Pure and Pharmaceutical Formulation
How to cite this article:
Roma N. Trivedi, Jinal N. Tandel, Samir K. Shah. Chemometrically Assisted RP-HPLC and Spectroscopic Method Development for Simultaneous Multi-Component Analysis of Ledipasvir and Sofosbuvir in Pure and Pharmaceutical Formulation. Journal of Pharmaceutical Research and Reviews, 2018; 2:10.
1 World Health Organization, WHO Global Hepatitis c report. Geneva, Switzerland: WHO. 2017
2 Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer. Hepatology – A clinical textbook; 8th Edn, 2017; 55-385.
3 Kirby BJ, Symonds WT, Kearney BP, Mathias AA. Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet, 2015; 54(7): 677-690.
4 Gilead Sciences, Inc. Harvoni (Ledipasvir and Sofosbuvir) tablets prescribing information. Foster City, CA, 2016 Feb.
5 Chem spider online. http://www.chemspider.co m/Chemical-Structure.26286922.html. (Accessed june 2017).
6 Chem spider online. http://www.chemspider.co m/Chemical-Structure.29271894.html?rid=6d1fd6b0-7b6c-42c9-95f2-6e5905933ee5. (Accessed june 2017).
7 Swain D, Samanthula G, Bhagat S, Bharatam PV, Akula V, et al. Characterisation of forced degradation products and in silico toxicity prediction of Sofosbuvir: a novel HCV NS5B polymerase inhibitor. J Pharm Biomed Anal, 2016; 120: 352-363.
8 Nebsen M, Elzanfaly ES. Stability-Indicating Method and LC-MSMS Characterization of Forced Degradation Products of Sofosbuvir. J Chromatogr Sci, 2016, 54(9): 1631-1640.
9 Joseph E Rower, Leah C Jimmerson, Xinhui Chen, Jia-Hua Zheng, Ariel Hodara, et al. Validation and application of an LC-MS/MS method to determine the concentrations of sofosbuvir. Antimicrobial Agents and Chemotherapy, 2015; 59(12): 7671-7679.
10 Rezk MR, Basalious EB, Amin ME. Novel and sensitive UPLCMS/MS method for quantification of Sofosbuvir in human plasma: application to a bioequivalence study. Biomed Chromatogr, 2016; 30: 13541362.
11 Rezk MR, Basalious EB, Karim IA. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: application to a bioequivalence study. J Pharm Biomed Anal, 2015; 114: 97-104.
12 Shi X, Zhu D, Lou J, Zhu B, Hu AR, et al. Evaluation of a rapid method for the simultaneous quantification of ribavirin, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci, 2015; 1002: 353-357.
13 Vikas PM, Satyanarayana T, Kumar DV, Mounika E, Sri LM, Sathish Y. Development and validation of new RP-HPLC method for the determination of sofosbuvirin pure form. World Journal of pharmacy and pharmaceutical Sciences, 2016; 5(5): 775-781.
14 Ravikumar Vejendla, CVS Subramanyam, G Veerabhadram. Estimation and validation of sofosbuvir in bulk and tablet dosage form by RP-HPLC. International Journal of Pharmacy, 2016; 6(2): 121-127.
15 Rezk MR, Bendas ER, Basalious EB, Karim IA. Development and validation of sensitive and rapid UPLC-MS/MS method for quantitative determination of daclatasvir in human plasma: Application to a bio equivalence study. J Pharm biomed Anal, 2016; 128: 61-6.
16 Ranjana S, Nitin S, Ganesh T, Gholve SB. Development and Validation of Simple UV Spectrophotometric Method for the Determination of Ledipasvir in Bulk Form and Stress Degradation Studies. Inventi Rapid: Pharm Analysis & Quality Assurance, 2016; 3: 1-5.
17 J Devilal, B Durgaprasad, Narottam Pal, A Srinivasa Rao. New method development and validation for the determination of ledipasvir in bulk drug form by using reverse phase HPLC technique. World Journal of pharmacy and pharmaceutical Sciences, 2016; 5(8): 13121321.
18 Rezk MR, Bendas ER, Basalious EB, Karim IA. Quantification of Sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: Application to fasting and fed bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci, 2016; 1028: 63-70.
19 Elkady, Ehab F., Aboelwafa, Ahmed A. A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma. Journal of AOAC International, 2016; 99(5).
20 Nehal F. Farid Nada S. Abdelwahab. Chromatographic Analysis of Ledipasvir and Sofosbuvir: New Treatment for Chronic Hepatitis C Infection with Application to Human Plasma. Journal of Liquid Chromatography & Related Technologies, 2017.
21 Ariaudo A, Favata F, De Nicolò A, Simiele M, Paglietti L, et al. A UHPLC-MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir in human plasma. .J Pharm biomed Anal, 2016; 125: 369-375.
22 Pan C, Chen Y, Chen W, Zhou G, Jin L, et al. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci, 2016; 1008: 255-259.
23 Zaman B, Siddique F, Hassan W. RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies. Chromatographia, 2016; 79(23): 1605-1613.
24 Mohamed El-Kassem M Hassouna et al. Assay and Dissolution Methods Development and Validation for Simultaneous Determination of Sofosbuvir and Ledipasvir by RP-HPLC Method in Tablet Dosage Forms. J Forensic Sci & Criminal Inves, 2017, 1(3).
25 International Conference on Harmonization. ICH Q2 (R1), Validation of analytical procedures: text and methodology, ICH Secretariat, Geneva, 2005.
26 United States Pharmacopeia 27, National Formulary 22, The United States Pharmacopoeial Convention, Rockville, 2003; 2: 2281.